Clinilabs Drug Development Corporation

Clinilabs Drug Development Corporation is the only global full-service contract research organisation (CRO) exclusively focused on central nervous system drug development, with over 25 years of experience managing Phase 1–3 trials across psychiatric, neurological, and substance-use disorders. It partnered with Cybin to conduct the first-in-human Phase 1/2a trial of CYB003, a deuterated psilocybin analog for major depressive disorder, obtaining DEA Schedule I licensing to support this psychedelic study.